Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +6.62%8 14-Day RSI is 52.29 as of Aug. 03, 2026. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 867 Medical Devices & Instruments companies, Alamar Biosciences ranks worse than 66.78% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Alamar Biosciences 14-Day RSI Related Terms
ALMR vs UFPT, BFLY, ENOV: 14-Day RSI Comparison
For the Medical Devices subindustry, Alamar Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alamar Biosciences (ALMR) has a 14-Day RSI of 52.29 as of Aug. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alamar Biosciences and its competitors. According to the industry distribution chart, Alamar Biosciences ranks #579 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 66.8%.
Is Alamar Biosciences' 14-Day RSI too high?
Alamar Biosciences' current 14-Day RSI is 52.29. The Medical Devices & Instruments industry median 14-Day RSI is 47.84. Alamar Biosciences' value of 52.29 is 9.3% above this industry median. Based on the distribution chart, Alamar Biosciences ranks #579 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' 14-Day RSI compare to UFPT and BFLY?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #579 out of 867 companies for 14-Day RSI. This places Alamar Biosciences in the lower half of its industry. The industry median 14-Day RSI is 47.84. Alamar Biosciences' value of 52.29 is 9.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.84, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alamar Biosciences's current 14-Day RSI of 52.29 is 9.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alamar Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alamar Biosciences's current 14-Day RSI is 52.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current 14-Day RSI of 52.29. The current 14-Day RSI is 52.29 and 9.3% above the Medical Devices & Instruments industry median of 47.84. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current 14-Day RSI is 52.29 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score
Get the complete analysis for ALMR
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
